Orexo AB (FRA:C5G) FCF Margin % : -9.81% (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Orexo AB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Orexo AB's Free Cash Flow for the three months ended in Sep. 2024 was €-1.18 Mil. Orexo AB's Revenue for the three months ended in Sep. 2024 was €12.02 Mil. Therefore, Orexo AB's FCF Margin % for the quarter that ended in Sep. 2024 was -9.81%.

As of today, Orexo AB's current FCF Yield % is -7.69%.

The historical rank and industry rank for Orexo AB's FCF Margin % or its related term are showing as below:

FRA:C5G' s FCF Margin % Range Over the Past 10 Years
Min: -98.02 Med: -17.7 Max: 30.44
Current: -7.73

During the past 13 years, the highest FCF Margin % of Orexo AB was 30.44%. The lowest was -98.02%. And the median was -17.70%.

FRA:C5G's FCF Margin % is ranked worse than
69.52% of 994 companies
in the Drug Manufacturers industry
Industry Median: 0.9 vs FRA:C5G: -7.73

Orexo AB FCF Margin % Historical Data

The historical data trend for Orexo AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orexo AB FCF Margin % Chart

Orexo AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

30.18

-26.05

-49.88

-28.91

-17.88

Orexo AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-18.32	-2.10	-14.43	-5.97	-9.81

Competitive Comparison of Orexo AB's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orexo AB's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Orexo AB's FCF Margin % falls into.

Orexo AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Orexo AB's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-10.209	/	57.107
	=	-17.88 %

Orexo AB's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-1.18	/	12.023
	=	-9.81 %

Orexo AB FCF Margin % Related Terms

Thank you for viewing the detailed overview of Orexo AB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orexo AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orexo AB (FRA:C5G) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ORXOY:USA ORXOF:USA ORX:Sweden

Address

Virdings alle 32 A, P.O. Box 303, Uppsala, SWE, 75105

Website

https://www.orexo.com

Orexo AB has operations in Sweden and the United States. Operations are monitored and presented in the segments USA Pharma, Digital Therapeutics (DTx), and HQ & Pipeline. The majority is from the USA Pharma segment. Geographically, the majority is derived from the United States. USA Pharma includes the commercialization of fully owned pharmaceuticals in the United States market. Digital Therapeutics include the commercialization of Orexo's groundbreaking evidence-based digital therapeutics, mainly in the United States market, which is in an early development stage. HQ &Pipeline includes the Development of pharmaceuticals performed at Orexo's headquarters in Uppsala, Sweden.

Orexo AB Headlines

No Headlines